ACTIVE_NOT_RECRUITING

PRISM Intervention Study

Talk to us

Conditions

Autism Spectrum DisorderautismJASPERDTTASDsocial and communication deficits

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study, Personalized, Responsive Intervention Sequences for Minimally Verbal Children with Autism (PRISM), is designed to maximize language outcomes for limited-language preschoolers, thereby lowering the risk of being classified as "minimally verbal" at age 6, by empirically developing a two-stage, 20-week adaptive intervention approach in a real world community settings. If found efficacious, the adaptive intervention design will capitalize on the heterogeneity and evolving status of children with ASD by providing the best intervention (DTT, JASPER and CET) for children who need it (leading to individualized sequences of intervention), only when it is needed (potentially reducing burden on children).

Official Title

Personalized, Responsive Intervention Sequences for Minimally Verbal Children With Autism

Quick Facts

Study Start:2021-03-01
Study Completion:2026-03-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT03883139

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:36 Months to 59 Months
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * children meeting ADOS-2 criteria for ASD,
  2. * age 36-59 months
  3. * who have had \> 3 months early intervention/preschool (to ensure that children already have been exposed to some community interventions) and
  4. * use \< 20 functional words (i.e., non-echoed, non-scripted).
  5. * stable medication over the past 6 months, and
  6. * nonverbal mental age of \>12 months on the Mullen Scales of Early Learning (visual reception and fine motor subscales).
  1. * We will exclude children who have sensory and motor impairments (e.g., visual impairment, deaf or hard of hearing) and with known genetic syndromes (e.g., Down Syndrome).
  2. * We will not exclude on the basis of AAC exposure, but expect few will be exposed at these ages.

Contacts and Locations

Study Locations (Sites)

UCLA
Los Angeles, California, 90095
United States
University of Rochester
Rochester, New York, 14642
United States
University of Oregon
Eugene, Oregon, 97403
United States

Collaborators and Investigators

Sponsor: University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-03-01
Study Completion Date2026-03-31

Study Record Updates

Study Start Date2021-03-01
Study Completion Date2026-03-31

Terms related to this study

Keywords Provided by Researchers

  • autism
  • JASPER
  • DTT
  • ASD
  • Autism Spectrum Disorder
  • social and communication deficits

Additional Relevant MeSH Terms

  • Autism Spectrum Disorder